返回 Agenda
The Journey to a Modernization of Analytics
Session Chair(s)
Peter Mesenbrink, PHD
Executive Director of Biostatistics
Novartis Pharmaceuticals Corporation, United States
This forum will present on the statistical analytics assessment framework based on risk as to the factors that contribute to confidence or trust for various statistical software, tools, and applications. A panel of experts will provide their experiences.
Learning Objective : Describe best practices to achieve a modernization of analytics within biostatistics and data science.
Speaker(s)
Changing How We Use Modern Analytics in Clinical Drug Development
Peter Mesenbrink, PHD
Novartis Pharmaceuticals Corporation, United States
Executive Director of Biostatistics
Industry Update
Daniel Woodie, MS
Merck & Co., Inc., United States
Senior Scientist, Statistical Programming
Industry Update
Andy Nicholls, MSC
GlaxoSmithKline, United Kingdom
Senior Director, Head of Statistical Data Sciences
Industry Update
Min Lee
Amgen, United States
Director of Biostatistical Programming